Wu Yingcheng, Xu Ran, Jia Keren, Shi Hui
Medical School of Nantong University, Jiangsu, China.
Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
PLoS One. 2017 Nov 15;12(11):e0187902. doi: 10.1371/journal.pone.0187902. eCollection 2017.
Most recently, an emerging theme in the field of tumor immunology predominates: chimeric antigen receptor (CAR) therapy in treating solid tumors. The number of related preclinical trials was surging. However, an evaluation of the effects of preclinical studies remained absent. Hence, a meta-analysis was conducted on the efficacy of CAR in animal models for solid tumors.
The authors searched PubMed/Medline, Embase, and Google scholar up to April 2017. HR for survival was extracted based on the survival curve. The authors used fixed effect models to combine the results of all the trials. Heterogeneity was assessed by I-square statistic. Quality assessment was conducted following the Stroke Therapy Academic Industry Roundtable standard. Publication bias was assessed using Egger's test.
Eleven trials were included, including 54 experiments with a total of 362 animals involved. CAR immunotherapy significantly improved the survival of animals (HR: 0.25, 95% CI: 0.13-0.37, P < 0.001). The quality assessment revealed that no study reported whether allocation concealment and blinded outcome assessment were conducted, and only five studies implemented randomization.
This meta-analysis indicated that CAR therapy may be a potential clinical strategy in treating solid tumors.
最近，肿瘤免疫学领域一个新出现的主题占据主导地位：嵌合抗原受体（CAR）疗法用于治疗实体瘤。相关的临床前试验数量激增。然而，对临床前研究的效果仍缺乏评估。因此，对CAR在实体瘤动物模型中的疗效进行了一项荟萃分析。
作者检索了截至2017年4月的PubMed/Medline、Embase和谷歌学术。基于生存曲线提取生存的风险比（HR）。作者使用固定效应模型合并所有试验的结果。通过I²统计量评估异质性。按照中风治疗学术产业圆桌会议标准进行质量评估。使用Egger检验评估发表偏倚。
纳入了11项试验，包括54项实验，共涉及362只动物。CAR免疫疗法显著提高了动物的生存率（HR：0.25，95%置信区间：0.13 - 0.37，P < 0.001）。质量评估显示，没有研究报告是否进行了分配隐藏和盲法结局评估，只有五项研究实施了随机化。
这项荟萃分析表明，CAR疗法可能是治疗实体瘤的一种潜在临床策略。
